KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO
KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO). Widely respected as an innovative biotech leader with a nearly 25-year track record of successfully inspiring colleagues and building organizations, J.D. will lead KBI and Selexis into the next chapter of becoming a leader in the next generation of CDMOs that are emerging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230417005167/en/
J.D. Mowery, KBI Biopharma and Selexis SA Chief Executive Officer (Photo: Business Wire)
“Through decades of service, J.D. has devoted his career to meaningful work with a clear focus on patient impact through the launch of novel therapies and by providing world-class service to manufacturing and development partners,” said Tim Lowery, President of JSR Life Sciences. “As we enter a pivotal growth phase, J.D. will play a crucial role in leading KBI and Selexis and empowering our global teams to succeed through servant leadership. We are confident his commitment to our long-term impact will guide us to greater success.”
J.D. will leverage his extensive global biopharmaceutical industry experience in operations, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. Previously having worked on both sides of the industry with innovators such as Genentech, Celgene, Juno, and most recently, Treadwell Therapeutics, as well as CDMOs Lonza and AGC Biologics, he acquired expertise across diverse modalities including small molecule, biologics, and cell and gene therapy.
“It is an honor to join KBI and Selexis at the perfect inflection point where we can leverage the collective knowledge, scientific expertise, and resources of the entire JSR ecosystem,” said J.D. “I’m fortunate to work with an amazingly talented team and energized that our current and future partners will see us positively disrupt the industry as an example of a true next-generation CDMO.”
J.D. finished, “I truly look forward to leading KBI and Selexis with a relentless focus on realizing our full potential for our people, partners, and most importantly, the patients across the globe that we serve together.”
J.D. will work closely with JSR leadership to ensure a seamless alignment of goals and continue to identify strategic growth opportunities within the larger JSR ecosystem.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
About Selexis SA
Selexis SA, a JSR Life Sciences company, is a global leader in mammalian cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. As part of a comprehensive drug development process, Selexis technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005167/en/
Contact information
KBI Biopharma, Inc. Company Inquiries
Leah Farmer
KBI Biopharma, Inc.
lfarmer@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Blair Ciecko
CG Life
bciecko@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NextPower V ESG Reaches $745 Million To Date29.4.2024 09:30:00 EEST | Press release
NextEnergy Capital (“NEC”), a leading global renewables manager specialised on the solar+ infrastructure sector, is delighted to announce the conclusion of its second close of $265 million for its fifth strategy, NextPower V ESG (“NPV ESG”). NPV ESG is an OECD-focused solar and battery storage strategy targeting $1.5 billion with a $2 billion hard cap that has secured $745 million in total commitments to date. The new capital includes commitments from a UK LGPS investment pool, a Dutch pension fund, and another re-up from an existing NextPower III ESG investor. These new investors join existing NPV ESG investors KLP, a German occupational pension fund, and a large Nordic pension fund. NPV ESG will continue welcoming further capital, with several investors currently active in due diligence. NPV ESG’s investment strategy targets the solar+ infrastructure sector in carefully selected OECD markets, with the objective of building significant portfolios in each target market, establishing an
H2SITE’s AMMONIA to H2POWER Technology Receives Approval in Principle From Lloyd’s Register29.4.2024 09:30:00 EEST | Press release
Ammonia cracking is gaining momentum as a potential hydrogen carrier for onboard applications and this system is based on H2SITE’s hydrogen-selective membranes that overcome the thermodynamic limitations of the ammonia cracking reaction by recovering hydrogen continuously and resulting in virtually complete ammonia conversion and higher efficiencies at lower temperatures, reducing overall energy consumption and footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428422597/en/ (Photo: Business Wire) In awarding the AIP, the design and arrangement evaluation included an overall examination of fundamental aspects of the design and compliance with LR’s Rules and Regulations for the Classification of Ships using Gases or other Low-flashpoint Fuels. A preliminary appraisal of rules was undertaken, followed by a risk assessment conducted to ensure that the risks arising from the use of ammonia and hydrogen are addressed ac
Geopolitical Stability, Inclusive Growth, Energy Security Under Spotlight in Riyadh at World Economic Forum Special Meeting29.4.2024 08:46:00 EEST | Press release
Riyadh convened global leaders today at the World Economic Forum Special Meeting on Global Collaboration, Growth and Energy for Development to host candid dialogues and outline bold steps to tackle the most pressing geopolitical, social and economic challenges facing humanity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428317713/en/ His Excellency Faisal Alibrahim, Saudi Minister of Economy and Planning, welcomes global leaders to Riyadh for the World Economic Forum Special Meeting on Global Collaboration, Growth and Energy for Development. (Photo: AETOSWire) Speaking at the Special Meeting, His Royal Highness Prince Abdulaziz bin Salman bin Abdulaziz Al Saud, Minister of Energy for Saudi Arabia, said a just and equitable energy transition will only be achieved by using a range of energy sources to diversify the global energy market. Access to secure and reliable energy, he said, is crucial to enabling people and comm
4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing29.4.2024 07:40:00 EEST | Press release
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/ (Graphic: Business Wire) With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model. Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the str
PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA29.4.2024 07:17:00 EEST | Press release
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.” PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom